Ferring Plots Genomics Path With Celmatix Pact
Executive Summary
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
You may also be interested in...
Ferring's New Chief Falk Talks
Ferring announced this morning (Oct. 31) that Michel Pettigrew is retiring as president of the executive board and will be succeeded by CSO Per Falk. The two spoke to Scrip recently and outlined the Swiss-based firm's future strategy.
Deal Watch: Mylan Clears Up Mystery, Acquires TOBI Cystic Fibrosis Products From Novartis
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.